2025.04.21
ONE-YEAR FOLLOW-UP RESULTS OF THE REGIST···
On April 18, 2025, at the China Valve (Hangzhou) 2025 conference, Prof. Yan Yunfeng from Prof. Song ···
2025.04.15
REGISTRATION APPLICATION FOR TaurusTrio™···
On April 14, 2025, Peijia Medical announced that the NMPA has formally accepted the registration app···
2025.04.08
HighLife granted US FDA Breakthrough Dev···
We are thrilled to congratulate our incredible partner HighLife Medical on receiving the U···
2025.03.05
SUCCESSFULLY COMPLETION OF THE FIRST TWO···
This announcement is made by Peijia Medical Limited (the “ Company”, together with itssubsidiaries, ···
2025.02.10
PROFESSOR GE JUNBO'S TEAM SUCCESSFULLY ···
The team led by Academician Ge Junbo from Zhongshan Hospitalaffiliated with Fudan University, includ···
2024.11.28
TaurusTrio™ TAVR SYSTEM (TaurusTrio™) SU···
In November 2024, Peijia Medical successfully implanted the TaurusTrio™, a self-developedtranscathet···
2024.11.26
PCR London Valves : HighLife® TSMVR SYST···
According to the clinical results, HighLife® achieved atechnical success rate of 89%. At 1 year, the···
2024.11.06
THE LATEST PROGRESS IN THE FIM STUDY OF ···
Since the first implantation in November 2023, a total
of 9 patients have been enrolled in MonarQ™ ···
2024.11.05
TWO-YEAR FOLLOW-UP RESULTS OF HighLife® ···
Two-year clinical data of the HighLife® TSMVR
technology's feasibility trial involving 30 cases···
2024.11.04
SmartWave LITHOTRIPSY VALVULOPLASTY TECH···
In the trial exploring the effectiveness and safety of
using the SmartWave lithotripsy valvuloplast···
2024.11.01
THE 2-YEAR RESULTS OF ALIGN-AR TRIAL OF ···
At 2 years, the cardiac mortality rate was still lower
than the study’s prespecified performance go···
2024.10.31
INTERPRETATION OF PRE-MARKET CLINICAL DA···
During October 24-27, 2024, the pre-market
clinical data for the YonFlow® flow diverter was
offici···
